Pharming Group has a consensus price target of $38.5 based on the ratings of 7 analysis. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on May 31, 2024, March 14, 2024, and August 3, 2023, respectively. With an average price target of $37 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 348.48% upside for Pharming Group from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/31/2024 | Buy Now | 348.48% | HC Wainwright & Co. | Joseph Pantginis | $37 → $37 | Reiterates | Buy → Buy | Get Alert |
03/14/2024 | Buy Now | 348.48% | HC Wainwright & Co. | Joseph Pantginis | → $37 | Reiterates | Buy → Buy | Get Alert |
08/03/2023 | Buy Now | 348.48% | HC Wainwright & Co. | Joseph Pantginis | → $37 | Reiterates | → Buy | Get Alert |
03/28/2023 | Buy Now | 384.85% | Oppenheimer | Michael Carrier | $36 → $40 | Maintains | Outperform | Get Alert |
03/27/2023 | Buy Now | 348.48% | HC Wainwright & Co. | Joseph Pantginis | → $37 | Reiterates | → Buy | Get Alert |
02/22/2023 | Buy Now | 348.48% | HC Wainwright & Co. | Joseph Pantginis | → $37 | Reiterates | → Buy | Get Alert |
02/16/2023 | Buy Now | 348.48% | HC Wainwright & Co. | Joseph Pantginis | → $37 | Reiterates | → Buy | Get Alert |
The latest price target for Pharming (NASDAQ:PHAR) was reported by HC Wainwright & Co. on May 31, 2024. The analyst firm set a price target for $37.00 expecting PHAR to rise to within 12 months (a possible 348.48% upside). 3 analyst firms have reported ratings in the last year.
The latest analyst rating for Pharming (NASDAQ:PHAR) was provided by HC Wainwright & Co., and Pharming reiterated their buy rating.
There is no last upgrade for Pharming
There is no last downgrade for Pharming.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pharming, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pharming was filed on May 31, 2024 so you should expect the next rating to be made available sometime around May 31, 2025.
While ratings are subjective and will change, the latest Pharming (PHAR) rating was a reiterated with a price target of $37.00 to $37.00. The current price Pharming (PHAR) is trading at is $8.25, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.